We are live on ! Find out more
FTH icon

Faeth Therapeutics
FTH

30 hedge funds and large institutions have $68M invested in Faeth Therapeutics in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

13,907% more capital inflows, than outflows

Capital inflows: $42.4M | Capital outflows: $303K

1,000% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 2

200% more funds holding

Funds holding: 10 → 30 (+20)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

167.15% more ownership

Funds ownership: 3.83% → 170.97% (+167%)

Holders
30
Holders Change
+20
Holders Change %
+200%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vivo Capital
Vivo Capital
California
+$14.4M
2
Cormorant Asset Management
Cormorant Asset Management
Massachusetts
+$6.12M
3
Millennium Management
Millennium Management
New York
+$2.93M
4
Franklin Resources
Franklin Resources
California
+$2.67M
5
Stempoint Capital
Stempoint Capital
New York
+$2.65M

Top Sellers

Rank Fund Capital Flow
1
Ikarian Capital
Ikarian Capital
Texas
-$300K
2
Citigroup
Citigroup
New York
-$3.14K
3
BNP Paribas
BNP Paribas
France
-$59

FTH Hedge Fund Activity: Q1 2026 in Review

30 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q1 2026, worth a combined $68M — up 13,104% from $515K a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new FTH positions and 2 closed out — a net gain of 20 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $14.4M. The largest seller was Ikarian Capital, cutting an estimated $300K.

  • 30 institutional investors held Faeth Therapeutics (FTH) as of Q1 2026, up from 10 in Q4 2025.
  • Funds reported $68M of Faeth Therapeutics stock for Q1 2026, up 13,104% quarter-over-quarter.
  • 22 funds opened new Faeth Therapeutics positions in Q1 2026 and 2 closed out, a net change of +20 holders.
  • The largest Faeth Therapeutics buyer in Q1 2026 was Vivo Capital, an estimated $14.4M added.
  • The largest Faeth Therapeutics seller in Q1 2026 was Ikarian Capital, an estimated $300K sold.

Based on aggregated 13F filings for Q1 2026.